|Description||BMS-186318 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb.|
|Synonyms||BMS-186318; BMS 186318; 12-Oxa-2,6,10-triazatetradecanoic acid, 4,8-dihydroxy-13,13-dimethyl-3-((4-(2-(4-morpholinyl)-2-oxoethoxy)phenyl)methyl)-11-oxo-9-(phenylmethyl)-, 1,1-dimethylethyl ester, (3S,4R,8R,9S)-; BMS-186318 analog 19; 12-Oxa-2,6,10-triazat|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
CC-3052, a thalidomide analogue, reduces persistent activation of the TNF-α system in HIV without markedly impairing neutrophil viability.
A potent inhibitor of HIV-l protease (IC50= 1 nM)
The hydrochloride salt form of MK-8718 which has been found to be a HIV protease inhibitor and could be studied in HIV research.
BMS-187071 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb.
CI-1029 is a nonpeptidic inhibitor of HIV protease, potenat against mutant HIV protease and resistant HIV strains.
DPC-681, sulfonamide derivatives, is an extremely potent and selective inhibitor of HIV protease. IC90s: wild-type HIV-1=4-40 nM
PD 099560, a benzopyran derivative, has been found to be a HIV-1 protease inhibitor that could be significant in HIV studies.
MK-8718 has been found to be a HIV protease inhibitor and could be studied in HIV research.
CGP-75355 is an HIV Protease inhibitor (EC50= 0.7 nM).
BMS-186318 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb.